Plural Six-membered Hetero Rings Consisting Of One Nitrogen And Five Carbon Atoms Patents (Class 514/332)
-
Patent number: 12180161Abstract: An 2-amino-4-(4-bromophenyl)-6-methoxypyridine-3,5-dicarbonitrile compound, its synthesis, and its use as an antibacterial agent.Type: GrantFiled: March 21, 2024Date of Patent: December 31, 2024Assignee: KING FAISAL UNIVERSITYInventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
-
Patent number: 12167994Abstract: The present invention relates to a compound according to Formula (I) or a salt, solvate and/or a hydrate thereof, wherein said compound inhibits dihydroorotate dehydrogenase (DHODH), for use in the treatment and prevention of viral infection. A preferred example is viral infection caused by coronavirus, in particular betacoronavirus, more particular SARS-CoV-2 and mutated versions thereof.Type: GrantFiled: July 1, 2022Date of Patent: December 17, 2024Assignee: IMMUNIC AGInventors: Manfred Gröppel, Daniel Vitt, Hella Kohlhof, Andreas Mühler
-
Patent number: 12102629Abstract: Nasally targeted dry powder compositions and methods for their use in the treatment of exposure to organophosphate compounds including chemical warfare agents and pesticides. Compositions include anticholinergic agents and cholinesterase reactivator agents used for primary treatment and vasoactive agents and benzodiazepines used for secondary treatment of exposure, and combinations of these agents. Compositions incorporate excipients and enabling agents such as permeation enhancers, and optimal sizing of active pharmaceutical ingredient particle size to improve drug delivery across the nasal mucosa, stability, and resistance to heat degradation. Packaging and configuration of devices for dry powder nasal compositions enable their use by non-medical personnel in civilian mass casualty or battlefield environments.Type: GrantFiled: September 2, 2022Date of Patent: October 1, 2024Assignee: BELHAVEN BIOPHARMA, INC.Inventors: Barry Bleske, Ted William Lanpher
-
Patent number: 12043597Abstract: The present disclosure encompasses crystalline polymorphs of Rivoceranib and Rivoceranib mesylate (Apatinib mesylate), processes for preparation thereof, and pharmaceutical compositions thereof.Type: GrantFiled: July 27, 2022Date of Patent: July 23, 2024Assignee: ASSIA CHEMICAL INDUSTRIES LTD.Inventors: Anantha Rajmohan Muthusamy, Sundara Lakshmi Kanniah, Elluru Subbireddy
-
Patent number: 11986465Abstract: A 2-amino-4-(4-bromophenyl)-6-ethoxypyridine-3,5-dicarbonitrile as an antibacterial compound, its synthesis, and its use as an antibacterial agent.Type: GrantFiled: November 9, 2023Date of Patent: May 21, 2024Assignee: KING FAISAL UNIVERSITYInventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
-
Patent number: 11926611Abstract: An 2-(2-ethoxyethoxy)-6-phenyl-4,4?-bipyridine-3-carbonitrile compound, its synthesis, and its use as an antimicrobial agent.Type: GrantFiled: November 24, 2023Date of Patent: March 12, 2024Assignee: KING FAISAL UNIVERSITYInventors: Mai Mostafa Khalaf, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed
-
Patent number: 11773058Abstract: The present invention relates to compounds of formula (I): Formula (I) wherein Q is selected from O or S; L is a saturated or unsaturated, optionally substituted C1-C12 hydrocarbylene group optionally including one or more heteroatoms N, O or S; R1 is —NR3R4, —OR5, —(C?NR6)R7, —(CO)R8, —CN, —N3, a quaternary ammonium group or an optionally substituted heterocycle; R3, R4, R5, R6, R7 and R8 are each independently hydrogen or a saturated or unsaturated, optionally substituted C1-C10 hydrocarbyl group optionally including one or more heteroatoms N, O or S; wherein optionally L and R3, or L and R4, or R3 and R4, or L and R5, or L and R6, or L and R7, or R6 and R7, or L and R8 together with the atom(s) to which they are attached may form a 3- to 12-membered, saturated or unsaturated, optionally substituted cyclic group; and R2 is a cyclic group substituted at the a-position, wherein R2 may optionally be further substituted; provided that the atom of L which is attached to the sulfur atom of the sulfonylurea groupType: GrantFiled: August 15, 2018Date of Patent: October 3, 2023Assignee: INFLAZOME LIMITEDInventors: David Miller, Angus MacLeod, Jimmy Van Wiltenburg, Stephen Thom, Stephen St-Gallay, Jonathan Shannon
-
Patent number: 11384104Abstract: The present invention provides a compound having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, for the controlled delivery and release of Agent.Type: GrantFiled: June 17, 2016Date of Patent: July 12, 2022Assignee: CENTURION BIOPHARMA CORPORATIONInventors: Felix Kratz, Khalid Abu Ajaj, André Warnecke, Stephan David Koester, Friederike I. Nollmann, Simon Waltzer, Olga Fuchs, Javier García Fernandez
-
Patent number: 11376232Abstract: The present invention relates to a compound according to Formula (I) or a salt, solvate and/or a hydrate thereof, wherein said compound inhibits dihydroorotate dehydrogenase (DHODH), for use in the treatment and prevention of viral infection. A preferred example is viral infection caused by coronavirus, in particular betacoronavirus, more particular SARS-CoV-2 and mutated versions thereof.Type: GrantFiled: April 20, 2021Date of Patent: July 5, 2022Assignee: Immunic AGInventors: Manfred Gröppel, Daniel Vitt, Hella Kohlhof, Andreas Mühler
-
Patent number: 11274080Abstract: The present invention describes novel diamino pyridine derivatives exhibiting JAK modulating properties. The present invention also relates to pharmaceutical compositions comprising these novel compounds, methods of using said compounds in the treatment of various diseases and disorders being susceptible to JAK modulation, and processes for preparing the compounds described hereinafter.Type: GrantFiled: January 8, 2020Date of Patent: March 15, 2022Assignee: Novartis AGInventor: Gebhard Thoma
-
Patent number: 10688087Abstract: A pharmaceutical composition for treatment of a pathological condition in a patient comprises, as a first component, a manganese complex of Formula I( ), and, as a second component, a non-manganese complex compound of Formula (I), optionally together with one or more physiologically acceptable carriers and/or excipients, wherein X, R, R, R, and R are as defined herein. Methods for treatment of a pathological condition in a patient, for example, a pathological condition caused by the presence of oxygen-derived free radicals, comprises administering to said patient the first component and the second component.Type: GrantFiled: July 6, 2010Date of Patent: June 23, 2020Assignee: PLEDPHARMA ABInventors: Jan-Olof Karlsson, Rolf Andersson
-
Patent number: 10653685Abstract: A pharmaceutical composition including N,N,N?,N?-tetrakis-(2-pyridylmethyl)-ethylenediamine (TPEN) or a pharmaceutically acceptable salt thereof, an alginate compound, and a pharmaceutically acceptable carrier. The pharmaceutical composition is useful for the treatment of hypoxia-related diseases.Type: GrantFiled: September 13, 2016Date of Patent: May 19, 2020Inventor: Jerachmiel Yori Appelbaum
-
Patent number: 10383849Abstract: The present invention relates to the use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in patients suffering from a CNS disease, in particular patients with Parkinson's disease, wherein balance, gait or movement is impaired.Type: GrantFiled: April 25, 2017Date of Patent: August 20, 2019Assignee: H. LUNDBECK A/SInventors: Inge E. M. de Jong, Aaron Kucinski, Martin Sarter
-
Patent number: 10034889Abstract: The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.Type: GrantFiled: August 16, 2016Date of Patent: July 31, 2018Assignees: CLIO, INC., TOHOKU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITYInventors: Mari Dezawa, Yoshinori Fujiyoshi, Masanori Yoshida
-
Patent number: 10011594Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.Type: GrantFiled: June 2, 2016Date of Patent: July 3, 2018Assignee: Bristol-Myers Squibb CompanyInventors: James A. Johnson, Soong-Hoon Kim, R. Michael Lawrence, Michael C. Myers, Hannguang J. Chao, Monique Phillips, Ji Jiang
-
Patent number: 9988355Abstract: The invention discloses a form A of mesylate for nicotinamide derivatives and preparation method and application thereof, wherein the XRPD pattern of the form A of mesylate for nicotinamide derivatives has a diffraction peak at 2?=5.34, 10.341, 14.438, 15.841, 17.32, 18.301, 18.68, 19.005, 19.577, 20.26, 21.161, 21.859, 22.379, 23.04, 23.5, 24.177, 24.959, 25.881, 26.641, 27.18, 28.3, 28.999, 29.501, 31.96, 32.258, 33.999, 36.798, 37.38 and 41.297 with the error range of the 2? values being ±0.2. The form A of mesylate for nicotinamide derivatives provided by the present invention has excellent high-temperature stability, high-humidity stability and illumination stability, and it can be applied to drugs for treating advanced non-small cell lung cancers, gastric cancers, liver cancer or breast cancer. It has preferable bioavailability, and meanwhile the provided qualitative and quantitative information has great significance on further study of the efficacy of such solid drugs.Type: GrantFiled: July 8, 2015Date of Patent: June 5, 2018Assignee: SHANGHAI SUNTRONG BIOTECHNOLOGY CO., LTD.Inventors: Yinglu Yu, Jinyao Chen, Dongxu Yi
-
Patent number: 9908878Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.Type: GrantFiled: June 9, 2016Date of Patent: March 6, 2018Assignee: Vertex Pharmaceuticals IncorporatedInventors: Paul S. Charifson, Michael P. Clark, Upul K. Bandarage, Randy S. Bethiel, Michael J. Boyd, Ioana Davies, Hongbo Deng, John P. Duffy, Luc J. Farmer, Huai Gao, Wenxin Gu, Joseph M. Kennedy, Brian Ledford, Mark W. Ledeboer, Francois Maltais, Emanuele Perola, Tiansheng Wang
-
Patent number: 9877954Abstract: The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: April 3, 2017Date of Patent: January 30, 2018Assignee: Bayer Pharma AktiengesellschaftInventors: Ulrich Lücking, Niels Böhnke, Arne Scholz, Philip Lienau, Gerhard Siemeister, Ulf Bömer, Dirk Kosemund, Rolf Bohlmann, Ludwig Zorn
-
Patent number: 9856242Abstract: The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: March 12, 2015Date of Patent: January 2, 2018Assignee: Bayer Pharma AktiengesellscaftInventors: Dirk Kosemund, Ulrich Lücking, Arne Scholz, Gerhard Siemeister, Philip Lienau
-
Patent number: 9770444Abstract: The present invention relates to a modulator of glucocorticoid biosynthesis, degradation and/or receptor activation for use in preventing or treating symptoms and/or diseases associated with jet lag. The compositions of the invention may be used as a lead compound for developing a drug for preventing or treating symptoms and/or diseases associated with jet lag. The invention relates to the discovery that administration of the modulator(s) to a subject results in a directional change of the time point of maximum amounts of glucocorticoids in the subject as compared to the time point of maximum amounts of glucocorticoids in a subject not treated with the modulator(s).Type: GrantFiled: December 17, 2014Date of Patent: September 26, 2017Assignee: MAX-PLANCK-GESELLSCHAFT-ZUR-FÖRDERUNG DER WISSENSCHAFTEN E.VInventors: Gregor Eichele, Henrik Oster, Silke Kiessling
-
Patent number: 9750731Abstract: Disclosed are methods and compositions for modulating the function of transcription factors, especially transcription factors that recruit epigenetic regulators (histone modifying enzymes) to specific DNA promoters. The targeted transcription factors include but are not limited to the myocyte enhancing factor (MEF2), the forkhead/winged helix transcription factor FOXP3 and the transcription factor GATA3. Also disclosed are small molecule modulators of MEF2 and its associated factors that include but not limited to histone deacetylases (HDACs), p300/CBP and Cabin1 and the therapeutic applications thereof.Type: GrantFiled: August 21, 2014Date of Patent: September 5, 2017Assignee: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Lin Chen, Nimanthi Jayathilaka, Aidong Han, Nicos Petasis
-
Patent number: 9701660Abstract: The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system.Type: GrantFiled: September 30, 2014Date of Patent: July 11, 2017Assignee: AC Immune S.A.Inventors: Heiko Kroth, Wolfgang Froestl, Andrea Pfeifer, Andreas Muhs
-
Patent number: 9656991Abstract: Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: A represents and B, R1, R2, R3, R4, R5, R6 and Z are as defined throughout the description and the claims.Type: GrantFiled: April 18, 2008Date of Patent: May 23, 2017Assignee: PROBIODRUG AGInventors: Mirko Buchholz, Ulrich Heiser, André J. Niestroj, Robert Sommer
-
Patent number: 9540323Abstract: The present invention provides compounds of Formula (I): Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor which may be used medicaments.Type: GrantFiled: July 30, 2013Date of Patent: January 10, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Alexandre L'Heureux, Sheldon Hiebert, Carol Hu, Patrick Y. S. Lam, John Lloyd, Zulan Pi, Jennifer X. Qiao, Carl Thibeault, George O. Tora, Wu Yang, Yufeng Wang, Tammy C. Wang, Michael S. Bowsher, Ruel Rejean
-
Patent number: 9458151Abstract: PIM kinase inhibitor compound having a structure as represented by Formula I, and isomers, diastereomers, enantiomers, tautomers, and pharmaceutically acceptable salts thereof. The compounds significantly inhibit the Pim kinase activity and are used to prepare drugs to treat PIM kinase mediated diseases, such as cancers, multi drug resistance, and inflammatory bowel disease. Also provided are methods for preparing and using the compounds represented by Formula I.Type: GrantFiled: June 22, 2015Date of Patent: October 4, 2016Assignee: Jikai Biosciences, Inc.Inventor: Yu Ge
-
Patent number: 9453003Abstract: PIM kinase inhibitor compound having a structure as represented by Formula I, and isomers, diastereomers, enantiomers, tautomers, and pharmaceutically acceptable salts thereof. The compounds significantly inhibit the Pim kinase activity and are used to prepare drugs to treat PIM kinase mediated diseases, such as cancers, multi drug resistance, and inflammatory bowel disease. Also provided are methods for preparing and using the compounds represented by Formula I.Type: GrantFiled: June 22, 2015Date of Patent: September 27, 2016Assignee: Jikai Biosciences, Inc.Inventor: Yu Ge
-
Patent number: 9447023Abstract: The invention relates to novel curcumin and tetrahydrocurcumin derivatives, which have been modified at one phenolic group to incorporate more-reactive groups. The curcumin and tetrahydrocurcumin derivatives are in the form of monomers, dimmers, and polymers.Type: GrantFiled: July 15, 2013Date of Patent: September 20, 2016Assignee: Research Foundation of the City University of New YorkInventors: Krishnaswami Raja, Probal Banerjee, Andrew Auerbach, Wei Shi, William L'Amoreaux
-
Patent number: 9446033Abstract: The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.Type: GrantFiled: February 28, 2014Date of Patent: September 20, 2016Assignees: CLIO, INC., TOHOKU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITYInventors: Mari Dezawa, Yoshinori Fujiyoshi, Masanori Yoshida
-
Patent number: 9187397Abstract: Curcumin analogues and methods are provided for treatment of disease.Type: GrantFiled: August 1, 2014Date of Patent: November 17, 2015Assignee: STC.UNMInventors: David L. Vander Jagt, Lorraine M. Deck, Steve F. Abcouwer, Robert A. Orlando, Robert E. Royer, Waylon M. Weber, Ekaterina V. Bobrovnikova-Marjon, Lucy A. Hunsaker
-
Patent number: 9156788Abstract: Disclosed herein are modulators of TRPV3 of formula (I) wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.Type: GrantFiled: February 7, 2013Date of Patent: October 13, 2015Assignee: AbbVie Inc.Inventors: Erol K. Bayburt, Bruce Clapham, Phil B. Cox, Jerome F. Daanen, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Eric A. Voight
-
Patent number: 9095582Abstract: The present application relates to novel substituted aryloxazole derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.Type: GrantFiled: May 14, 2013Date of Patent: August 4, 2015Assignee: Bayer Intellectual Property GmbHInventors: Peter Nell, Walter Hübsch, Barbara Albrecht-Küpper, Jorg Keldenich, Alexandros Vakalopoulos, Frank Süssmeier, Katja Zimmermann, Dieter Lang, Daniel Meibom
-
Patent number: 9096525Abstract: Compounds of the formula I in which the substituents are as defined in claim 1 are suitable for use as microbiocides.Type: GrantFiled: August 20, 2013Date of Patent: August 4, 2015Assignee: Syngenta Crop Protection, LLCInventors: Paul Anthony Worthington, Daniel Stierli, Fredrik Cederbaum, Kurt Nebel, Antoine Daina
-
Patent number: 9090561Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.Type: GrantFiled: September 13, 2012Date of Patent: July 28, 2015Assignee: ARIAD Pharmaceuticals, Inc.Inventors: Yihan Wang, Xiaotian Zhu, Rajeswari Sundaramoorthi, Wei-Sheng Huang, Dong Zou, R. Mathew Thomas, Jiwei Qi, Jan Antoinette C. Romero, David C. Dalgarno, William C. Shakespeare, Tomi K. Sawyer, Chester A. Metcalf, III
-
Patent number: 9079889Abstract: New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.Type: GrantFiled: November 15, 2013Date of Patent: July 14, 2015Assignee: NOVARTIS AGInventors: Matthew T. Burger, Wooseok Han, Jiong Lan, Gisele Nishiguchi
-
Publication number: 20150141462Abstract: The present invention relates to pharmaceutical compositions comprising (a) a pharmaceutically effective amount of an mGluR5 positive allosteric modulator, derivative, prodrug or a pharmaceutically acceptable salt thereof; (b) a pharmaceutically effective amount of an agent selected from an NMDA partial agonist or a GlyT1 inhibitor, derivative, prodrug or a pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier. The present invention also relates to methods for treating drug addiction and preventing a drug relapse in a patient.Type: ApplicationFiled: June 11, 2013Publication date: May 21, 2015Inventor: M. Foster Olive
-
Publication number: 20150141433Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR2A subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.Type: ApplicationFiled: September 26, 2014Publication date: May 21, 2015Inventors: David R. Anderson, Robert A. Volkmann
-
Publication number: 20150133473Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: May 20, 2013Publication date: May 14, 2015Applicant: NOVARTIS AGInventors: Matthew Burger, Joseph E. Drumm III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
-
Patent number: 9028873Abstract: The present disclosure relates to compositions and methods for producing nanoparticles to provide relatively more rapid delivery of such particles across the blood-brain barrier. The nanoparticles may be formed from bis-quaternary pyridinium-aldoxime salts that may also be of a specific polymorphic structure and which may be formed in either hydrophobic or hydrophilic type liquid media. In addition, the nanoparticle for transport across the blood-brain barrier may comprise a polymeric resin encapsulating a bis-quaternary pyridinium-2-aldoxime salt.Type: GrantFiled: February 8, 2010Date of Patent: May 12, 2015Assignee: Southwest Research InstituteInventors: Joseph A. McDonough, Hong Dixon, Larry A. Cabell
-
Publication number: 20150126557Abstract: The invention relates to octenidine or a pharmaceutical salt thereof, in particular octenidine dihydrochloride, which is intended for mutual therapeutic administration of the octenidine in solution with a polyalcohol of formula (1a) or (1b): (H—C—OH)a(HO—C—OH)b(H—C—H)c(CHO)??(1a), (H—C—OH)a(HO—C—OH)b(H—C—H)c(CO)??(1b), wherein a, b, c are whole numbers, where a+b is at least 2, preferably at least 3, c is selected from 0, 1 or a number from 2 to a+b, provided that the aldehyde group of formula (1a) is in a form of an acetal with one of the hydroxy groups or the keto group of formula (1b) is in a form of an acetal with one of the hydroxy groups. The invention also relates to kits containing these ingredients, and use thereof for treating infections and wounds.Type: ApplicationFiled: October 30, 2014Publication date: May 7, 2015Applicant: ARTAN HOLDING AGInventor: Ahmet Melih AYDINOGLU
-
Patent number: 9017735Abstract: Disclosed herein are compositions and methods for treating a psychiatric disorder or symptoms thereof in a patient. The compositions comprise a compound that modulates KCNQ (Kv7) potassium channel activity and the methods include administering an effective amount of the compound that modulates KCNQ (Kv7) potassium channel activity.Type: GrantFiled: June 3, 2010Date of Patent: April 28, 2015Assignee: Marquette UniversityInventor: Mohammadhossein Behnam Ghasemzadeh
-
Patent number: 9018233Abstract: The invention relates to diaminoaryl derivatives substituted by carbamate, salts thereof and a pesticidal composition containing the same, which exhibit superior pest control effects against various insect pests of insect species, in particular against moths such as the diamondback moth or Spodoptera litura.Type: GrantFiled: May 7, 2013Date of Patent: April 28, 2015Assignees: Kyung Nong Corporation, Korea Research Institute of Chemical TechnologyInventors: Sung Youn Chang, Jung Nyoung Heo, Hyuk Lee, Hwan Jung Lim, Bum Tae Kim, Joo Kyung Kim, Jong-Kwan Kim
-
Publication number: 20150111879Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.Type: ApplicationFiled: December 24, 2014Publication date: April 23, 2015Applicants: CURIS, INC., GENENTECH, INC.Inventors: Janet L. GUNZNER, Daniel P. SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
-
Publication number: 20150104496Abstract: The present invention relates to a composition containing at least one nutritive, at least one disinfecting or decontaminating and/or at least one protease-inhibiting active compound and/or active compound complex for the external care and/or treatment of wounds of the human or animal body.Type: ApplicationFiled: October 21, 2014Publication date: April 16, 2015Inventor: Birgit RIESINGER
-
Publication number: 20150105427Abstract: A compound of formula (Ie?): wherein Ar?, R1, R4e and Y are as defined herein and a method of controlling pests using the compound.Type: ApplicationFiled: December 17, 2014Publication date: April 16, 2015Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Shinzo KAGABU, Masaaki MITOMI, Shigeki KITSUDA, Ryo HORIKOSHI, Masahiro NOMURA, Yasumichi ONOZAKI
-
Publication number: 20150105428Abstract: The present invention relates to a modulator of glucocorticoid biosynthesis, degradation and/or receptor activation for use in preventing or treating symptoms and/or diseases associated with jet lag. The compositions of the invention may be used as a lead compound for developing a drug for preventing or treating symptoms and/or diseases associated with jet lag. The invention relates to the discovery that administration of the modulator(s) to a subject results in a directional change of the time point of maximum amounts of glucocorticoids in the subject as compared to the time point of maximum amounts of glucocorticoids in a subject not treated with the modulator(s).Type: ApplicationFiled: December 17, 2014Publication date: April 16, 2015Inventors: Gregor Eichele, Henrik Oster, Silke Kiessling
-
Patent number: 9006269Abstract: Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: Wherein Ar1 is optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Ar2 is optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Ar3 is a divalent radical selected from the group consisting of optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms.Type: GrantFiled: April 19, 2013Date of Patent: April 14, 2015Assignee: Vernalis (R&D) Ltd.Inventors: Stephen Roughley, Steven Walls, Terance Hart, Rachel Parsons, Paul Brough, Christopher Graham, Alba Macias
-
Publication number: 20150094338Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.Type: ApplicationFiled: December 5, 2014Publication date: April 2, 2015Applicant: PFIZER INC.Inventors: Gary Erik Aspnes, Mary Theresa Didiuk, Kevin James Filipski, Angel Guzman-Perez, Jeffrey Allen Pfefferkorn, Benjamin Dawson Stevens, Meihua Mike Tu
-
Patent number: 8980925Abstract: The present invention is directed to compositions useful for antimicrobial applications. These compositions comprise amphiphilic compounds.Type: GrantFiled: October 20, 2011Date of Patent: March 17, 2015Assignee: James Madison Innovations, Inc.Inventors: Kevin P. Minbiole, Kevin L. Caran, Kyle N. Seifert
-
Publication number: 20150073021Abstract: The present invention provides a method of inhibiting the binding of anthrax lethal factor with protective antigen comprising contacting the anthrax lethal factor with a compound having the structure:Type: ApplicationFiled: September 5, 2014Publication date: March 12, 2015Applicants: The Research Foundation for The State University of New York, Chem-Master International, Inc.Inventors: Anthony ANTONELLI, Sanford R. SIMON, Yu ZHANG, Lorne M. GOLUB, Francis JOHNSON
-
Publication number: 20150057288Abstract: A pest control method for honeybee parasitic pests has been found, which is highly safe to honeybees and demonstrates excellent pest control effects against honeybee parasitic pests by using a honeybee parasitic pest control agent containing at least one of a compound represented by Formula (I) and acid addition salts thereof.Type: ApplicationFiled: November 10, 2014Publication date: February 26, 2015Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Ryo HORIKOSHI, Masaaki MITOMI